<DOC>
	<DOCNO>NCT00088192</DOCNO>
	<brief_summary>To provide Pegaptanib sodium injection patient subfoveal choroidal neovascularization ( CNV ) secondary AMD , unable participate Sponsor ’ clinical study drug AMD , time patient ’ lesion consider resolve stabilized opinion treat ophthalmologist , product becomes commercially available .</brief_summary>
	<brief_title>Intravitreous Pegaptanib Sodium Injection Patients With Exudative Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Best correct visual acuity study eye 20/40 20/320 . Subfoveal choroidal neovascularization , secondary age relate macular degeneration , total lesion size [ include blood , scar/atrophy &amp; neovascularization ] &lt; 12 total disc area , least 50 % must active CNV . Any subretinal hemorrhage must comprise 50 % total lesion size . General Criteria : Patients either gender , age great 50 year . Women must use two form effective contraception , postmenopausal least 12 month prior study entry , surgically sterile . If childbearing potential , serum pregnancy test must perform within 48 hour prior treatment result make available prior treatment initiation . The two form effective contraception must implement study least 60 day follow last dose test medication . Written informed consent . Any subfoveal scarring atrophy 25 % total lesion size may make scar atrophy . Patients eligible PDT Visudyne Patients eligible Sponsor ’ ongoing AMD study still open enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Exudative Subfoveal Age Related Macular Degeneration Subfoveal Choroidal Neovascularization</keyword>
</DOC>